Dynavax Technologies Corp (DVAX)
11.76
+0.14
(+1.16%)
USD |
NASDAQ |
May 07, 16:00
11.76
0.00 (0.00%)
After-Hours: 20:00
Dynavax Technologies Revenue (Quarterly): 55.60M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 55.60M |
| September 30, 2023 | 69.51M |
| June 30, 2023 | 60.25M |
| March 31, 2023 | 46.92M |
| December 31, 2022 | 184.49M |
| September 30, 2022 | 167.74M |
| June 30, 2022 | 256.46M |
| March 31, 2022 | 113.99M |
| December 31, 2021 | 195.07M |
| September 30, 2021 | 108.27M |
| June 30, 2021 | 52.77M |
| March 31, 2021 | 83.34M |
| December 31, 2020 | 19.55M |
| September 30, 2020 | 13.41M |
| June 30, 2020 | 2.668M |
| March 31, 2020 | 10.92M |
| December 31, 2019 | 10.57M |
| September 30, 2019 | 10.58M |
| June 30, 2019 | 8.301M |
| March 31, 2019 | 5.773M |
| December 31, 2018 | 5.318M |
| September 30, 2018 | 1.461M |
| June 30, 2018 | 1.254M |
| March 31, 2018 | 0.165M |
| December 31, 2017 | 0.021M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.053M |
| June 30, 2017 | 0.105M |
| March 31, 2017 | 0.148M |
| December 31, 2016 | 7.292M |
| September 30, 2016 | 0.162M |
| June 30, 2016 | 2.647M |
| March 31, 2016 | 0.942M |
| December 31, 2015 | 0.685M |
| September 30, 2015 | 1.188M |
| June 30, 2015 | 1.55M |
| March 31, 2015 | 0.627M |
| December 31, 2014 | 2.277M |
| September 30, 2014 | 2.209M |
| June 30, 2014 | 3.048M |
| March 31, 2014 | 3.498M |
| December 31, 2013 | -2.291M |
| September 30, 2013 | 2.927M |
| June 30, 2013 | 3.392M |
| March 31, 2013 | 2.085M |
| December 31, 2012 | -2.133M |
| September 30, 2012 | 2.874M |
| June 30, 2012 | 2.684M |
| March 31, 2012 | 2.35M |
| December 31, 2011 | 11.43M |
| September 30, 2011 | 1.174M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.668M
Minimum
Jun 2020
256.46M
Maximum
Jun 2022
77.39M
Average
55.60M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| Supernus Pharmaceuticals Inc | 164.31M |
| Esperion Therapeutics Inc | 32.25M |
| Deciphera Pharmaceuticals Inc | 48.29M |
| Ligand Pharmaceuticals Inc | 28.10M |
| Pacira BioSciences Inc | 181.24M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.219M |
| Total Expenses (Quarterly) | 64.09M |
| Enterprise Value | 999.45M |
| Gross Profit Margin (Quarterly) | 84.37% |
| Profit Margin (Quarterly) | 0.39% |
| Earnings Yield | -0.51% |
| Normalized Earnings Yield | 0.0928 |